Subgroup analysis based on tumor type indicated that higher expression of LAG3 was correlated with worse PFS in patients with BLCA (HR = 1.58, 95% CI 1.12–2.23, P = 0.010) and SARC (HR = 1.10, 95% CI 1.02–1.19, P = 0.016). The gene discussed is LAG3; the disease is bladder transitional cell carcinoma.